39,000 Shares in Heron Therapeutics Inc (NASDAQ:HRTX) Purchased by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale bought a new position in Heron Therapeutics Inc (NASDAQ:HRTX) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 39,000 shares of the biotechnology company’s stock, valued at approximately $1,505,000.

Several other large investors have also added to or reduced their stakes in the company. Norges Bank purchased a new stake in Heron Therapeutics during the 4th quarter valued at about $13,679,000. Boston Advisors LLC grew its position in Heron Therapeutics by 443.9% during the 1st quarter. Boston Advisors LLC now owns 134,559 shares of the biotechnology company’s stock valued at $3,288,000 after purchasing an additional 109,819 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its position in Heron Therapeutics by 144.6% during the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 19,690 shares of the biotechnology company’s stock valued at $511,000 after purchasing an additional 11,640 shares during the last quarter. American Century Companies Inc. grew its position in Heron Therapeutics by 1.7% during the 4th quarter. American Century Companies Inc. now owns 134,526 shares of the biotechnology company’s stock valued at $3,490,000 after purchasing an additional 2,278 shares during the last quarter. Finally, Legal & General Group Plc grew its position in Heron Therapeutics by 6.5% during the 4th quarter. Legal & General Group Plc now owns 27,564 shares of the biotechnology company’s stock valued at $716,000 after purchasing an additional 1,679 shares during the last quarter.

Shares of HRTX stock traded up $0.35 on Monday, reaching $18.94. The company’s stock had a trading volume of 819,600 shares, compared to its average volume of 1,028,110. The stock’s fifty day simple moving average is $17.88. Heron Therapeutics Inc has a 1 year low of $16.20 and a 1 year high of $41.55. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.40 and a quick ratio of 4.06. The stock has a market capitalization of $1.47 billion, a P/E ratio of -7.76 and a beta of 1.59.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.30). Heron Therapeutics had a negative return on equity of 49.22% and a negative net margin of 194.43%. The company had revenue of $31.60 million during the quarter, compared to the consensus estimate of $28.04 million. During the same quarter in the prior year, the business earned ($1.09) earnings per share. The firm’s quarterly revenue was up 172.4% compared to the same quarter last year. On average, research analysts expect that Heron Therapeutics Inc will post -2.66 earnings per share for the current year.

HRTX has been the topic of several recent analyst reports. Northland Securities set a $55.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Stifel Nicolaus restated a “buy” rating and set a $38.00 target price on shares of Heron Therapeutics in a research note on Wednesday, May 1st. Cowen restated a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, May 9th. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 22nd. Finally, Cantor Fitzgerald cut shares of Heron Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, March 4th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $48.20.

In other news, Director Waage Christian acquired 1,400 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The stock was purchased at an average cost of $18.04 per share, for a total transaction of $25,256.00. Following the completion of the acquisition, the director now directly owns 1,400 shares of the company’s stock, valued at approximately $25,256. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Poyhonen acquired 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was purchased at an average price of $17.55 per share, with a total value of $52,650.00. Following the completion of the acquisition, the director now directly owns 13,000 shares of the company’s stock, valued at $228,150. The disclosure for this purchase can be found here. 12.56% of the stock is currently owned by company insiders.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Story: How is a buy-side analyst different from a sell-side analyst?

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.